Kimozo (Temozolomide)

Temozolomide is a pro‑drug that converts to a methylating agent in the bloodstream. This agent adds a methyl group to the O6 position of guanine in DNA, causing mismatched base pairing and DNA strand breaks. The resulting damage triggers apoptosis in rapidly dividing tumor cells, reducing tumor growth.

The specific dose and schedule of temozolomide are determined by the prescribing physician based on the patient’s condition, body surface area, and treatment protocol. Dosing may differ between initial radiotherapy‑combined regimens and subsequent adjuvant cycles, and should always follow the clinician’s written order.

Temozolomide is classified as contraindicated during pregnancy because it can cause fetal harm. Women of child‑bearing potential should use effective contraception during treatment and for a period after the last dose. Limited data are available for breastfeeding, and the drug is generally not recommended while nursing.

To order Kimozo, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After the request, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including any cold‑chain requirements), and import documentation.

Temozolomide is an oral alkylating agent that offers the convenience of oral administration compared with intravenous agents such as carmustine. It has demonstrated survival benefit when combined with radiotherapy for newly diagnosed glioblastoma. While other agents like bevacizumab target angiogenesis, temozolomide directly damages tumor DNA, making it a cornerstone of standard glioma therapy.

Kimozo should be stored at temperatures below 25 °C, in its original packaging, and protected from moisture and direct sunlight. Keep the product out of reach of children and avoid crushing or breaking tablets. If any degradation is observed, discard the product according to local regulations.

Kimozo is taken orally, usually with water, and may be administered with or without food depending on the prescribing instructions. The tablets are swallowed whole; they should not be chewed, split, or dissolved unless specifically directed by a healthcare professional.

The most serious risks include severe bone‑marrow suppression leading to neutropenia or thrombocytopenia, which can increase infection or bleeding risk, and rare but potentially fatal liver toxicity. Patients should be monitored regularly for blood counts and liver function, and any signs of infection, unusual bruising, or jaundice should prompt immediate medical evaluation.

Temozolomide should not be used by individuals who are pregnant, have known hypersensitivity to the drug or its excipients, or have uncontrolled severe infections. Caution is also advised for patients with significant bone‑marrow, liver or renal impairment, and those receiving concurrent therapies that markedly suppress hematopoiesis.